Brought to you by 
Amgen buys Immunex in $17.9bn cash and stock deal
Feb 2003
Executive Summary
In a tax-free deal that brings together two of the largest biotech players, Amgen will acquire most of Immunex (inflammation) for $17.9bn. It will exchange 0.44 share of Amgen common stock and $4.50 cash for each Immunex share.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Contract
- Payment Includes Cash
- Partial Acquisition
- Payment Includes Stock
- Intra-Biotech Deal
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen buys Immunex in $17.9bn cash and stock deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice